Assessment of Renal Function in Post-Liver Transplant HCV-Positive Patients Treated with Direct Acting Antivirals

References

• Organization, W.H.. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. 2018.
   Google Scholar
• Modin L, Arshad A, Wilkes B, et al. Epidemiology and natural history of hepatitis C virus infection among children and young people. J Hepatol. 2019;70(3):371–378. doi:10.1016/j.jhep.2018.11.01330496763
   PubMed Web of Science ®Google Scholar
• Germani G, Tsochatzis E, Papastergiou V, Burroughs A. HCV in liver transplantation. Semin Immunopathol. 2013;35:101–110. doi:10.1007/s00281-012-0329-522829333
   PubMed Web of Science ®Google Scholar
• Narang TK, Ahrens W, Russo MW. Post–liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria. Liver Transpl. 2010;16(11):1228–1235. doi:10.1002/lt.2217521031537
   PubMed Web of Science ®Google Scholar
• Daniel KE, Said A. Considerations when treating hepatitis C in a cirrhotic transplant candidate. Curr Gastroenterol Rep. 2018;20(5):20. doi:10.1007/s11894-018-0626-929623506
   PubMedGoogle Scholar
• Gurusamy KS, Tsochatzis E, Xirouchakis E, Burroughs AK, Davidson BR. Antiviral therapy for recurrent liver graft infection with hepatitis C virus. Cochrane Library. 2010.
   Web of Science ®Google Scholar
• Liver EAFTSOT. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66(1):153.27667367
   PubMed Web of Science ®Google Scholar
• Chung R, Davis G, Jensen D. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62(3):932–954.26111063
   PubMed Web of Science ®Google Scholar
• Majumdar A, Kitson M, Roberts S. Systematic review: current concepts and challenges for the direct‐acting antiviral era in hepatitis C cirrhosis. Aliment Pharmacol Ther. 2016;43(12):1276–1292.27087015
   PubMed Web of Science ®Google Scholar
• Peschel G, Moleda L, Baier L, et al. Safety of direct-acting antiviral therapy regarding renal function in post–liver transplant patients infected with Hepatitis C virus and a 100% 12-week sustained virologic response—a single-center study In: Transplantation Proceedings. 2018;50(5):1444–1450.
   Google Scholar
• Charlton M, Gane E, Manns P, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015;148(1):108–117. doi:10.1053/j.gastro.2014.10.00125304641
   PubMed Web of Science ®Google Scholar
• Pungpapong S, Aqel B, Leise M. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology. 2015;61(6):1880–1886. doi:10.1002/hep.2777025722203
   PubMed Web of Science ®Google Scholar
• Charlton M, Everson G, Steven L, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149(3):649–659. doi:10.1053/j.gastro.2015.05.01025985734
   PubMed Web of Science ®Google Scholar
• Leroy V, Dumortier J, Coilly A, et al. Efficacy of sofosbuvir and daclatasvir in patients with fibrosing cholestatic hepatitis C after liver transplantation. Clin Gastroenterol Hepatol. 2015;13(11):1993–2001. e2. doi:10.1016/j.cgh.2015.05.03026044317
   PubMed Web of Science ®Google Scholar
• Fontana RJ, Brown RS, Moreno-Zamora A, et al. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. Liver Transpl. 2016;22(4):446–458. doi:10.1002/lt.2441626890629
   PubMed Web of Science ®Google Scholar
• Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence. Hepatology. 2016;63(5):1493–1505. doi:10.1002/hep.2844626754432
   PubMed Web of Science ®Google Scholar
• Reau N, Kwo PY, Rhee S. MAGELLAN-2: safety and efficacy of glecaprevir/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1–6 infection. J Hepatol. 2017;66(1):S90–S91. doi:10.1016/S0168-8278(17)30444-0
   Web of Science ®Google Scholar
• Nada A, Abbasy M, Sabry A, et al. Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-positive Egyptian patients treated with sofosbuvir. Can J Gastroenterol Hepatol. 2020;2020:1–7. doi:10.1155/2020/1632959
   Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612. doi:10.7326/0003-4819-150-9-200905050-0000619414839
   PubMed Web of Science ®Google Scholar
• Andrews LM, Riva N, de Winter BC, et al. Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients. Expert Opin Drug Metab Toxicol. 2015;11(6):921–936. doi:10.1517/17425255.2015.103339725865963
   PubMed Web of Science ®Google Scholar
• Gadiparthi C, Cholankeril G, Perumpail BJ, et al. Use of direct-acting antiviral agents in hepatitis C virus-infected liver transplant candidates. World J Gastroenterol. 2018;24(3):315. doi:10.3748/wjg.v24.i3.31529391754
   PubMed Web of Science ®Google Scholar
• Picciotto FP, Tritto G, Lanza AG, et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol. 2007;46(3):459–465. doi:10.1016/j.jhep.2006.10.01717196700
   PubMed Web of Science ®Google Scholar
• Ferrarese A, Zanetto A, Gambato M, et al. Liver transplantation for viral hepatitis in 2015. World J Gastroenterol. 2016;22(4):1570. doi:10.3748/wjg.v22.i4.157026819523
   PubMed Web of Science ®Google Scholar
• Coilly A, Roche B, Duclos-Vallée JC, Samuel D. Optimum timing of treatment for hepatitis C infection relative to liver transplantation. Lancet Gastroenterol Hepatol. 2016;1(2):165–172. doi:10.1016/S2468-1253(16)30008-528404073
   PubMed Web of Science ®Google Scholar
• Samur S, Kues B, Ayer T, et al. Cost effectiveness of pre–vs post–liver transplant hepatitis C treatment with direct-acting antivirals. Clin Gastroenterol Hepatol. 2018;16(1):115–122. e10. doi:10.1016/j.cgh.2017.06.02428634131
   PubMed Web of Science ®Google Scholar
• Levitsky J, Verna EC, O’Leary JG, et al. Perioperative ledipasvir-sofosbuvir for HCV in liver-transplant recipients. N Engl J Med. 2016;375(21):2106. doi:10.1056/NEJMc161182927959735
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Charlton M, et al. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. Lancet Gastroenterol Hepatol. 2016;1(2):122–132. doi:10.1016/S2468-1253(16)30009-728404069
   PubMed Web of Science ®Google Scholar
• Ferenci P. Treatment of hepatitis C in difficult-to-treat patients. Nat Rev Gastroenterol Hepatol. 2015;12(5):284. doi:10.1038/nrgastro.2015.5325895822
   PubMed Web of Science ®Google Scholar
• Skoglund C, Lagging M, Castedal M, Kanda T. No need to discontinue hepatitis C virus therapy at the time of liver transplantation. PLoS One. 2019;14(2):e0211437. doi:10.1371/journal.pone.021143730794555
   PubMed Web of Science ®Google Scholar
• Rupp C, Hippchen T, Neuberger M, et al. Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus. World J Gastroenterol. 2018;24(12):1353. doi:10.3748/wjg.v24.i12.135329599610
   PubMed Web of Science ®Google Scholar
• D’Ambrosio R, Aghemo A, Rumi MG, et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology. 2012;56(2):532–543. doi:10.1002/hep.2560622271347
   PubMed Web of Science ®Google Scholar
• Welsch C, Efinger M, von Wagner M, et al. Ongoing liver inflammation in patients with chronic hepatitis C and sustained virological response. PLoS One. 2017;12(2):e0171755. doi:10.1371/journal.pone.017175528196130
   PubMed Web of Science ®Google Scholar
• Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4(2):481–508. doi:10.2215/CJN.0480090819218475
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Aghemo A, Fogazzi GB, et al. Acute tubular necrosis following interferon-based therapy for hepatitis C: case study with literature review. Kidney Blood Press Res. 2013;38(1):52–60. doi:10.1159/00035575324556714
   PubMed Web of Science ®Google Scholar
• Kökény S, Papp J, Weber G, Vaszkó T, Carmona-Saez P, Oláh E. Ribavirin acts via multiple pathways in inhibition of leukemic cell proliferation. Anticancer Res. 2009;29(6):1971–1980.19528454
   PubMed Web of Science ®Google Scholar
• Sato K, Naganuma A, Nagashima T, et al. Elevated serum uric acid level was a notable adverse event during combination therapy with sofosbuvir and ribavirin. Hepatol Res. 2018;48(3):E347–e353. doi:10.1111/hepr.1297128834004
   PubMed Web of Science ®Google Scholar
• Knorr JP, Chewaproug D, Neeli S, Torres E, Zaki R. Severe interferon/ribavirin-induced hyperuricemia and urate nephropathy requiring rasburicase and hemodialysis in a liver transplant recipient. Exp Clin Transplant. 2015;13(6):596–599.25806515
   PubMed Web of Science ®Google Scholar
• Harambat J, Dubourg L, Ranchin B, et al. Hyperuricemia after liver transplantation in children. Pediatr Transplant. 2008;12(8):847–853. doi:10.1111/j.1399-3046.2008.00950.x18537903
   PubMed Web of Science ®Google Scholar
• Ciesek S, Proske V, Otto B, et al. Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation. Transpl Infect Dis. 2016;18(3):326–332. doi:10.1111/tid.1252426988272
   PubMed Web of Science ®Google Scholar
• Pillai AA, Maheshwari R, Vora R, et al. Treatment of HCV infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin. Aliment Pharmacol Ther. 2017;45(11):1427–1432. doi:10.1111/apt.1405928382751
   PubMed Web of Science ®Google Scholar
• Shoreibah O, John Romano J, Sims TM, et al. Effect of Hepatitis C treatment on renal function in liver transplant patients. J Clin Transl Hepatol. 2018;6(4):391–395.30637216
   PubMed Web of Science ®Google Scholar
• Mansour M, Hill L, Kerr J. Safety and effectiveness of direct acting antivirals for treatment of hepatitis C virus in patients with solid organ transplantation. Transpl Infect Dis. 2018;20(6):e12972. doi:10.1111/tid.1297230080955
   PubMed Web of Science ®Google Scholar